Report
Kristoffer Inton
EUR 101.80 For Business Accounts Only

Trimming Kinross Gold’s FVE After Updating Our Production Forecasts for Latest Projects

On Sept. 18, Kinross Gold announced its decision to proceed with Tasiast’s Phase Two expansion and Round Mountain’s Phase W expansion. While the development projects should help add important ounces to Kinross in the long term, the company continues to face declining production at a few other mines. Given its recent debt raise in July, we don’t think the company will need additional financing to pay for the expansion projects.
We forecast production to decline from about 2.6 million ounces in 20...
Underlying
Kinross Gold Corporation

Kinross Gold is engaged in the mining and processing of gold and, as a by-product, silver ore and the exploration for, and the acquisition of, gold bearing properties in the Americas, the Russian Federation, West Africa and worldwide. As of Dec 31 2013, Co.'s proven mineral reserves for gold and silver were 1,122 ounces and 1,179 ounces respectively.7,883 7,883 7,883

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Kristoffer Inton

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch